Celltrion wins EU recommendation to expand Steqeyma’s pediatric indications
South Korean biopharmaceutical company Celltrion Inc. said Monday that its biosimilar Steqeyma (CT-P43), has received a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to expand its approved uses to children with Crohn’s disease and ulcerative colitis aged 2 and older.
The recommendation covers an expanded label for Steqeyma, a biosimilar of Johnson & Johnson’s autoimmune disease drug Stelara, whose active ingredient is ustekinumab. Final approval procedures remain.
The expansion would broaden Steqeyma’s treatment coverage in Europe to younger pediatric patients. The drug is already approved there for several conditions, including plaque psoriasis in adults and children, psoriatic arthritis in adults, and Crohn’s disease and ulcerative colitis in adults, as well as Crohn’s disease in children weighing at least 40 kilograms.
“We will complete the remaining approval procedures and expand our portfolio of interleukin inhibitors to strengthen our position in the global autoimmune disease market,” said a company official.
Stelara generated around $6.08 billion in sales last year. The global ustekinumab market was estimated at $18.67 billion in 2025, according to pharmaceutical market research firm IQVIA.